DE69712745T2 - Pyrrolopyrimidinen und verfahren zu deren herstellung - Google Patents

Pyrrolopyrimidinen und verfahren zu deren herstellung

Info

Publication number
DE69712745T2
DE69712745T2 DE69712745T DE69712745T DE69712745T2 DE 69712745 T2 DE69712745 T2 DE 69712745T2 DE 69712745 T DE69712745 T DE 69712745T DE 69712745 T DE69712745 T DE 69712745T DE 69712745 T2 DE69712745 T2 DE 69712745T2
Authority
DE
Germany
Prior art keywords
formula
substituted
dilower
alkyl
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69712745T
Other languages
German (de)
English (en)
Other versions
DE69712745D1 (de
Inventor
Guido Bold
Joerg Frei
Peter Traxler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Erfindungen Verwaltungs GmbH
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfindungen Verwaltungs GmbH, Novartis AG filed Critical Novartis Erfindungen Verwaltungs GmbH
Application granted granted Critical
Publication of DE69712745D1 publication Critical patent/DE69712745D1/de
Publication of DE69712745T2 publication Critical patent/DE69712745T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DE69712745T 1996-01-23 1997-01-13 Pyrrolopyrimidinen und verfahren zu deren herstellung Expired - Lifetime DE69712745T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH17596 1996-01-23
PCT/EP1997/000127 WO1997027199A1 (en) 1996-01-23 1997-01-13 Pyrrolopyrimidines and processes for their preparation

Publications (2)

Publication Number Publication Date
DE69712745D1 DE69712745D1 (de) 2002-06-27
DE69712745T2 true DE69712745T2 (de) 2002-10-31

Family

ID=4180979

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69712745T Expired - Lifetime DE69712745T2 (de) 1996-01-23 1997-01-13 Pyrrolopyrimidinen und verfahren zu deren herstellung

Country Status (9)

Country Link
US (1) US6140317A (enExample)
EP (1) EP0888349B1 (enExample)
JP (1) JP4275733B2 (enExample)
AT (1) ATE217873T1 (enExample)
AU (1) AU1441497A (enExample)
DE (1) DE69712745T2 (enExample)
ES (1) ES2177925T3 (enExample)
PT (1) PT888349E (enExample)
WO (1) WO1997027199A1 (enExample)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
DE69738468T2 (de) 1996-08-23 2009-01-08 Novartis Ag Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
WO1998014450A1 (en) 1996-10-02 1998-04-09 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
ATE221886T1 (de) * 1997-09-02 2002-08-15 Bristol Myers Squibb Pharma Co Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ES2356886T3 (es) 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
TW505646B (en) 1998-06-19 2002-10-11 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
HK1047236A1 (zh) * 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
AU2001259707A1 (en) 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
PL359563A1 (pl) 2000-06-26 2004-08-23 Pfizer Products Inc. Związki pirolo [2,3-d] pirymidynowe jako środki immunosupresyjne
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
KR100875380B1 (ko) * 2001-06-23 2008-12-23 아벤티스 파마슈티칼스 인크. 단백질 키나제 억제제로서의 피롤로피리미딘
WO2003037897A2 (en) * 2001-10-29 2003-05-08 Novartis Ag Use of 7h-pyrrolo[2,3-d]pyrimidine derivatives in the treatment of solid tumor diseases
WO2004047843A1 (en) 2002-11-26 2004-06-10 Pfizer Products Inc. Method of treatment of transplant rejection
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
WO2004093812A2 (en) * 2003-04-22 2004-11-04 Irm Llc Compounds that induce neuronal differentiation in embryonic stem cells
CN1972712A (zh) 2003-06-09 2007-05-30 塞缪尔·瓦克萨尔 用胞外拮抗物和胞内拮抗物抑制受体酪氨酸激酶的方法
US20050239806A1 (en) * 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
CN1980934B (zh) * 2004-05-03 2011-10-26 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物
EP1797054A2 (en) * 2004-08-02 2007-06-20 OSI Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20090111805A1 (en) * 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
PT2100618E (pt) 2005-06-17 2014-04-07 Philadelphia Health & Educatio Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
JP2009505658A (ja) 2005-08-24 2009-02-12 ブリストル−マイヤーズ スクイブ カンパニー 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法
CA2662937A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
US20080161320A1 (en) * 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
CN101528746A (zh) * 2006-09-15 2009-09-09 先灵公司 治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物
CN101583612A (zh) * 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
JP2010503678A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション アゼチジノン誘導体およびその使用方法
WO2009098715A2 (en) 2008-01-11 2009-08-13 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
EP2384326B1 (en) 2008-08-20 2014-04-23 Zoetis LLC Pyrrolo[2,3-d]pyrimidine compounds
MX2011004824A (es) 2008-11-07 2012-01-12 Triact Therapeutics Inc Uso de derivados de butano catecólico en terapia contra el cáncer.
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
WO2011053779A2 (en) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
JP2013510564A (ja) 2009-11-13 2013-03-28 パンガエア ビオテック、ソシエダッド、リミターダ 肺癌におけるチロシンキナーゼ阻害剤に対する応答を予測するための分子バイオマーカー
EP2468883A1 (en) 2010-12-22 2012-06-27 Pangaea Biotech S.L. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
WO2012106522A2 (en) 2011-02-04 2012-08-09 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2492688A1 (en) 2011-02-23 2012-08-29 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
GB201106870D0 (en) 2011-04-26 2011-06-01 Univ Belfast Marker
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
US20130084287A1 (en) 2011-09-30 2013-04-04 Genentech, Inc. Diagnostic markers
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013190089A1 (en) 2012-06-21 2013-12-27 Pangaea Biotech, S.L. Molecular biomarkers for predicting outcome in lung cancer
AU2013312477B2 (en) * 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
EP3237638B1 (en) 2014-12-24 2020-01-15 F.Hoffmann-La Roche Ag Therapeutic, diagnostic and prognostic methods for cancer of the bladder
WO2018078143A1 (en) 2016-10-28 2018-05-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
NZ754994A (en) 2016-12-22 2022-12-23 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3099118A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3790886B1 (en) 2018-05-10 2024-06-26 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
EP3802535B1 (en) 2018-06-01 2022-12-14 Amgen, Inc Kras g12c inhibitors and methods of using the same
CA3099799A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
ES3051918T3 (en) 2019-08-02 2025-12-30 Amgen Inc Kif18a inhibitors
JP7640521B2 (ja) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
WO2021026098A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
CN114391012B (zh) 2019-08-02 2025-10-31 美国安进公司 作为kif18a抑制剂的吡啶衍生物
EP4048671B1 (en) 2019-10-24 2026-03-18 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
EP4054719B1 (en) 2019-11-04 2026-02-11 Revolution Medicines, Inc. Ras inhibitors
KR20220109407A (ko) 2019-11-04 2022-08-04 레볼루션 메디슨즈, 인크. Ras 억제제
JP7823816B2 (ja) 2019-11-04 2026-03-04 レヴォリューション・メディスンズ，インコーポレイテッド Ｒａｓ阻害剤
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
WO2021097207A1 (en) 2019-11-14 2021-05-20 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
CA3183032A1 (en) 2020-06-18 2021-12-23 Mallika Singh Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
IL308193A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2025500878A (ja) 2021-12-17 2025-01-15 ジェンザイム・コーポレーション Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
IL314883A (en) 2022-03-07 2024-10-01 Amgen Inc A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
PE20251879A1 (es) 2022-10-14 2025-07-22 Black Diamond Therapeutics Inc Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
PE20260039A1 (es) 2023-04-07 2026-01-09 Revolution Medicines Inc Inhibidores macrociclicos de ras
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970009225B1 (ko) * 1989-09-19 1997-06-09 데이진 가부시끼가이샤 피롤로[2,3-디] 피리미딘 유도체, 그의 제조방법 및 그것을 유효성분으로 하는 의약제제
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AU686843B2 (en) * 1994-02-23 1998-02-12 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
EP0682027B1 (de) * 1994-05-03 1997-10-15 Novartis AG Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
AU711592B2 (en) * 1995-04-03 1999-10-14 Novartis Ag Pyrazole derivatives and processes for the preparation thereof
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
ATE212993T1 (de) * 1995-07-06 2002-02-15 Novartis Erfind Verwalt Gmbh Pyrolopyrimidine und verfahren zu ihrer herstellung
CN1237177A (zh) * 1996-11-27 1999-12-01 辉瑞大药厂 稠合的二环嘧啶衍生物

Also Published As

Publication number Publication date
JP4275733B2 (ja) 2009-06-10
AU1441497A (en) 1997-08-20
WO1997027199A1 (en) 1997-07-31
ATE217873T1 (de) 2002-06-15
JP2000503005A (ja) 2000-03-14
EP0888349A1 (en) 1999-01-07
US6140317A (en) 2000-10-31
ES2177925T3 (es) 2002-12-16
EP0888349B1 (en) 2002-05-22
PT888349E (pt) 2002-10-31
DE69712745D1 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
DE69712745T2 (de) Pyrrolopyrimidinen und verfahren zu deren herstellung
DE69619114T2 (de) Pyrolopyrimidine und verfahren zu ihrer herstellung
DE69738468T2 (de) Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
EP0682027B1 (de) Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
DE69732780T2 (de) Pyrimiderivate und verfahren zu ihrer herstellung
DE60101158T2 (de) 8-chinolinxanthin and 8-isochinolinxanthin derivate als pde 5 inhibitoren
DE60209721T2 (de) Oxazolo- und furopyrimidine und deren verwendung als medikamente gegen tumore
KR20170023156A (ko) 단백질 키나제 저해제로서의 아미노피리다지논 화합물
JP6667014B2 (ja) ピリミジン誘導体、その調製方法および医療での使用
DE602004004550T2 (de) Substituierte heterocyclische verbindungen und anwendungsverfahren
CA2242354C (en) Pyrrolopyrimidines and processes for their preparation
KR102933542B1 (ko) Egfr 키나아제를 억제하기 위한 화합물, 이의 제조 방법 및 용도
AU707626C (en) Pyrrolopyrimidines and processes for the preparation thereof
TW472057B (en) Pyrrolopyrimidines and processes for the preparation thereof
HK1008222B (en) Pyrrolopyrimidines and processes for the preparation thereof
DE10122895A1 (de) Neue Lactam-substituierte Pyrazolopyridinderivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN